Biogen Idec Research Limited — Sponsor Intelligence | 20 EU Trials

Filter these 20 trials by condition, phase, country and more.

Open in Search →

20 Registered trials

4 Recruiting

15 Completed trials

20 Countries active

27 Unique IMPs

100% Results reported

Phase III

Phase II

Phase III: 12 Phase II/III: 1 Phase II: 4 Phase IV: 1 Phase I: 1 Phase I (Other): 1

Oversight events:

1 corrective measure across 1 trial

View oversight register →

100%

15 of 15 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Systemic lupus erythematosus 3 Subacute cutaneous lupus erythematosus 2 Cutaneous lupus erythematosus 2 Chronic cutaneous lupus erythematosus 2 Relapsing-remitting multiple sclerosis 2 Relapsing multiple sclerosis 1 Amyotrophic lateral sclerosis 1 Familial amyotrophic lateral sclerosis 1 Parkinson's disease 1 Spinal muscular atrophy 1 Retinitis pigmentosa 1 IgA nephropathy 1

Top IMPs

LITIFILIMAB 5 NUSINERSEN 4 2ʹ-O-(2-METHOXYETHYL) ANTISENSE OLIGONUCLEOTIDE TARGETING MICROTUBULE-ASSOCIATED PROTEIN TAU PRE-MRNA 2 FLORBETABEN (18F) 2 FLUTEMETAMOL (18F) 2 (R)-1-(TERT-BUTYL)-N-(8-(2-((1-METHYL-1H-PYRAZOL-4-YL)AMINO)PYRIMIDIN-4-YL)-2-(OXETAN-3-YL)-2,3,4,5-TETRAHYDRO-1H-BENZO[C]AZEPIN-5-YL)-1H-1,2,3-TRIAZOLE-4-CARBOXAMIDE 1 6-(FLUORO-18F)-3-(1H-PYRROLO[2,3-C]PYRIDIN-1-YL)-5-ISOQUINOLINAMINE 1 BIIB115 1 DIMETHYL FUMARATE 1 DIROXIMEL FUMARATE 1 FELZARTAMAB 1 GADOTERIC ACID 1

All trials

20 total

A Study to Assess if BIIB080 Can Change Clinical Dementia Rating-Sum of Boxes Scores, and BIIB080 Safety and Tolerability When Injected Into… Not authorised

2022-501644-15-00 Phase II 11 countries 2ʹ-O-(2-METHOXYETHYL) ANTISENSE OLIGONUCLEOTIDE TARGETING MICROTUBULE-ASSOCIATED…
A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants… Recruiting

2024-514239-21-00 Phase I (Other) 5 countries NUSINERSEN
A Phase 3 study of Omaveloxolone in participants with Friedreich’s Ataxia Ages 2 < 16 years Recruiting

2025-520896-13-00 Phase III 8 countries OMAVELOXOLONE
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) ( PREVAIL ) Recruiting

2024-519345-30-00 Phase III 11 countries FELZARTAMAB
A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adul… Recruiting

2023-504863-17-00 Phase III 11 countries LITIFILIMAB
A Study to Learn About the Safety of BIIB080 and Whether it Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzhe… Ended

2022-501644-15-01 Phase II 11 countries 2ʹ-O-(2-METHOXYETHYL) ANTISENSE OLIGONUCLEOTIDE TARGETING MICROTUBULE-ASSOCIATED…
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB115. Ended

2023-505643-39-00 Phase I 6 countries BIIB115
A Study to Evaluate the Efficacy and Safety of BIIB059 in Participants With Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cut… Ended

2023-505634-94-00 Phase II/III 11 countries LITIFILIMAB
A Study to Evaluate Higher Dose (HD) Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy Previously Treated With Risdiplam (AS… Ended

2023-505639-11-00 Phase III 3 countries NUSINERSEN
A Study to Evaluate the Continuous Safety and Efficacy of Litifilimab (BIIB059) in Adults With Active Systemic Lupus Erythematosus (EMERALD) Ended

2023-505635-13-00 Phase III 13 countries LITIFILIMAB
A Study to Evaluate the Efficacy and Safety of BIIB059 in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background N… Ended

2023-505696-74-00 Phase III 7 countries LITIFILIMAB
A Study to Evaluate the Efficacy and Safety of BIIB059 (Litifilimab) in Adult Participants With Active Systemic Lupus Erythematosus Receivin… Ended

2023-505695-30-00 Phase III 6 countries LITIFILIMAB
A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation (ATLAS) Ended

2023-505641-12-00 Phase III 6 countries TOFERSEN
Extension Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy Who Previously Participated in a Study With Nusinersen … Ended

2023-505637-27-00 Phase III 3 countries NUSINERSEN
A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon beta-1a) in Pediatric Participants for the Treatment of… Ended

2023-505624-56-00 Phase III 5 countries INTERFERON BETA-1A; PEGINTERFERON BETA-1A
A Long-term Follow-up Study to Evaluate the Safety and Efficacy of Retinal Gene Therapy in Subjects with Choroideremia Previously Treated wi… Ended

2023-507994-16-00 Phase III 2 countries TIMREPIGENE EMPARVOVEC
A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adult… Ended

2022-502552-31-00 Phase II 7 countries (R)-1-(TERT-BUTYL)-N-(8-(2-((1-METHYL-1H-PYRAZOL-4-YL)AMINO)PYRIMIDIN-4-YL)-2-(O…
A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of BIIB122 in participants … Ended

2023-505645-12-00 Phase II 7 countries N2-(3-(2-(2H-1,2,3-TRIAZOL-2-YL)PROPAN-2-YL)-1-CYCLOPROPYL-1H-PYRAZOL-5-YL)-N4-E…
A Study of Nusinersen Among Participants With Spinal Muscular Atrophy Who Received Onasemnogene Abeparvovec (RESPOND) Ended

2023-505640-18-00 Phase IV 3 countries NUSINERSEN
Phase 3 Efficacy and Safety Study of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS). Ended

2023-505632-35-00 Phase III 1 country DIMETHYL FUMARATE

Showing 1–20 of 20 trials

← All sponsors A–Z